Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors

Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of lung tumors, providing a new and precise evaluation method for lung malignant tumors.

NCT Number	NCT07487883
Lead Sponsor	Peking University People's Hospital
Conditions	Non-Small Cell Lung Cancer, Malignant Neoplasm, Pulmonary Nodules, PET/CT
Enrollment	80 participants
Start Date	2026-03-18
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-02